Part 2: PGx is the study of how genetic variations influence a person’s response to medicines, being efficacy or safety. The goal of CERSI-PGx, led by Sir Munir Pirmohamed, is to enable PGx innovation deliver a medicine fit for your genome through bringing together all stakeholders and ensuring that we empower them through education to harness the innovations shaping this new era of medicine.
Innovation and regulatory science go hand in hand — one drives progress in medicine; the other ensures that progress is safe, effective, and reaches the patients.
The Project team here at BPS are working alongside subject matter experts at the University of Liverpool and Queen Mary University of London, who are contributing their expertise and longstanding knowledge in the field of PGx to produce these modules and shape the course content.
At Our CERSI innovation takes the form of PGx and our goal is to create proportionate, forward-looking, inclusive and responsive regulatory pathways to streamline clinical implementation and support growth.
Part 3: Collaborating for Change: Inside the Development of Our PGx Training Programme
By Kemi Webster and Rebecca Jensen, Subject Matter Experts
The Project team here at BPS are working alongside subject matter experts at the University of Liverpool and Queen Mary University of London, who are contributing their expertise and longstanding knowledge in the field of pharmacogenomics to produce these modules and shape the course content.
Kemi Webster, Clinical Pharmacist and Teaching Fellow at Queen Mary University of London, and Rebecca Jensen, Postdoctoral Researcher and Lecturer at the University of Liverpool, have been creating and developing the content for the eLearning modules.
We have covered the basics of pharmacogenomic principles, with practical case studies to encompass real-world applications. This also includes up-to-date research on genetic variations which can affect drug efficacy and toxicity with interactive quizzes to solidify learning. We have signposted to other useful resources if users would like to delve deeper into the topics too.
Rebecca: “From a researcher’s perspective, pharmacogenomics is at the forefront of advancing drug development for personalised medicine. As we uncover genetic factors which can influence drug response, there’s an increasing need for researchers to integrate these insights into their projects, to improve patient outcomes.”
Kemi: “Pharmacogenomics is rapidly becoming an essential clinical tool, helping clinicians choose the right medication the first time. By tailoring treatments to each patient’s genetic profile, it supports better outcomes, reduces trial-and-error prescribing, and lowers the risk of adverse drug reactions.”
We are proud of the team and all the hard work that went into creating this content. It’s designed to be accessible, engaging, and practical so you can immediately apply what you learn.
Check the platform here: portal.bpsassessment.com/cersi-pgx-elearning-portal/
